A share price of Cns Pharmaceuticals Inc [CNSP] is currently trading at $0.11, up 0.09%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CNSP shares have gain 4.63% over the last week, with a monthly amount drifted -2.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cns Pharmaceuticals Inc [NASDAQ: CNSP] stock has seen the most recent analyst activity on December 28, 2020, when Ladenburg Thalmann downgraded its rating to a Neutral. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on August 24, 2020, and set its price target to $11.
Cns Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $0.10 and $65.50. Currently, Wall Street analysts expect the stock to reach $0.5 within the next 12 months. Cns Pharmaceuticals Inc [NASDAQ: CNSP] shares were valued at $0.11 at the most recent close of the market. An investor can expect a potential return of 354.55% based on the average CNSP price forecast.
Analyzing the CNSP fundamentals
Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at -2684.89%, Pretax Profit Margin comes in at -2681.03%, and Net Profit Margin reading is -2681.03%. To continue investigating profitability, this company’s Return on Assets is posted at -2.3, Equity is 6.96 and Total Capital is -5.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1093 points at the first support level, and at 0.1057 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1153, and for the 2nd resistance point, it is at 0.1177.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cns Pharmaceuticals Inc [NASDAQ:CNSP] is 1.81. In addition, the Quick Ratio stands at 1.81 and the Cash Ratio stands at 1.72.
Transactions by insiders
Recent insider trading involved Gumulka Jerzy, Director, that happened on Feb 01 ’24 when 33333.0 shares were purchased. Director, Evans Carl Anthony completed a deal on Feb 01 ’24 to buy 33333.0 shares. Meanwhile, Chief Financial Officer Downs Christopher bought 66666.0 shares on Feb 01 ’24.
